Literature DB >> 1350281

The p88 molecular chaperone is identical to the endoplasmic reticulum membrane protein, calnexin.

N Ahluwalia1, J J Bergeron, I Wada, E Degen, D B Williams.   

Abstract

We previously described a novel molecular chaperone (designated p88) that participates in the assembly of murine class I histocompatibility molecules (Degen, E., and Williams, D. B. (1991) J. Cell Biol. 112, 1099-1115). Our findings suggest that p88 may either promote proper assembly of class I molecules or retain them, probably within the endoplasmic reticulum (ER), until assembly of the ternary complex of heavy chain, beta 2-microglobulin, and peptide ligand is complete. In this report, we compare p88 to calnexin, a calcium-binding 90-kDa phosphoprotein of the ER membrane (Wada, I., Rindress, D., Cameron, P. H., Ou, W.-J., Doherty, J.-J., II, Louvard, D., Bell, A.W., Dignard, D., Thomas, D. Y., and Bergeron, J. J. M. (1991) J. Biol. Chem. 266, 19599-19610). We show that p88 and calnexin share antigenic epitopes defined by a polyclonal anti-calnexin antiserum. Furthermore, both proteins were immunoprecipitated in association with an intracellularly retained variant of the class I H-2Kb molecule. Since p88 and calnexin were also indistinguishable by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis, were resistant to digestion with endoglycosidase H, and exhibited virtually identical patterns of peptide fragments following digestion with either V8 protease or trypsin, we conclude that p88 and calnexin represent the same protein. The identification of the p88 chaperone as a phosphorylated, calcium-binding protein of the ER membrane suggests possible means whereby its interaction with class I molecules may be regulated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350281

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

Review 1.  Protein quality control in the early secretory pathway.

Authors:  Tiziana Anelli; Roberto Sitia
Journal:  EMBO J       Date:  2008-01-23       Impact factor: 11.598

2.  Raft-like membranes from the trans-Golgi network and endosomal compartments.

Authors:  Mark G Waugh
Journal:  Nat Protoc       Date:  2013-11-07       Impact factor: 13.491

3.  Stoichiometric tapasin interactions in the catalysis of major histocompatibility complex class I molecule assembly.

Authors:  Naveen Bangia; Peter Cresswell
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

Review 4.  Endogenous antigen presentation by MHC class II molecules.

Authors:  A J Sant
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

5.  In vivo expression of mammalian BiP ATPase mutants causes disruption of the endoplasmic reticulum.

Authors:  L M Hendershot; J Y Wei; J R Gaut; B Lawson; P J Freiden; K G Murti
Journal:  Mol Biol Cell       Date:  1995-03       Impact factor: 4.138

Review 6.  How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum.

Authors:  A Helenius
Journal:  Mol Biol Cell       Date:  1994-03       Impact factor: 4.138

7.  Detergent-free isolation and characterization of cholesterol-rich membrane domains from trans-Golgi network vesicles.

Authors:  Mark G Waugh; K M Emily Chu; Emma L Clayton; Shane Minogue; J Justin Hsuan
Journal:  J Lipid Res       Date:  2010-12-29       Impact factor: 5.922

8.  Yip1A structures the mammalian endoplasmic reticulum.

Authors:  Kaitlyn M Dykstra; Jacqueline E Pokusa; Joseph Suhan; Tina H Lee
Journal:  Mol Biol Cell       Date:  2010-03-17       Impact factor: 4.138

9.  Human papillomavirus type 16 infection of human keratinocytes requires clathrin and caveolin-1 and is brefeldin a sensitive.

Authors:  Valerie Laniosz; Sarah A Dabydeen; Mallory A Havens; Patricio I Meneses
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

10.  Hepatitis C virus glycoprotein folding: disulfide bond formation and association with calnexin.

Authors:  J Dubuisson; C M Rice
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.